Roth Capital started coverage on shares of Apexigen (NASDAQ:APGN – Get Rating) in a research report report published on Tuesday morning, The Fly reports. The brokerage issued a buy rating and a $15.00 target price on the stock.

Other equities analysts also recently issued research reports about the company. EF Hutton Acquisition Co. I initiated coverage on Apexigen in a research note on Thursday, January 5th. They issued a buy rating and a $8.00 price objective on the stock. Brookline Capital Management reiterated a buy rating on shares of Apexigen in a research note on Monday, December 12th.

Apexigen Trading Up 8.7 %

Apexigen stock opened at $1.99 on Tuesday. Apexigen has a 52 week low of $0.61 and a 52 week high of $31.35. The business's 50 day moving average price is $1.42.

Institutional Trading of Apexigen

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Decheng Capital Management III Cayman LLC purchased a new stake in Apexigen during the 3rd quarter worth about $5,115,000. Citadel Advisors LLC purchased a new stake in Apexigen during the 3rd quarter worth about $141,000. BlackRock Inc. purchased a new stake in Apexigen during the 3rd quarter worth about $577,000. Vanguard Group Inc. purchased a new stake in Apexigen during the 3rd quarter worth about $692,000. Finally, Two Sigma Investments LP purchased a new stake in Apexigen during the 3rd quarter worth about $38,000. 28.88% of the stock is currently owned by institutional investors.

Apexigen Company Profile

(Get Rating)

Apexigen Inc, a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and rectal and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells.

Further Reading

• Get a free copy of the StockNews.com research report on Apexigen (APGN)
• Is It Time To Get Aggressive With Defense Stocks?
• When Will Crane Holdings Take Flight?
• 3 Retail Stocks Ringing the Register in 2023
• Qualcomm Gets a Boost from Analysts, but is it Time to Buy?
• EVgo Stock is Charged Up to Ride the EV Adoption Wave

Receive News & Ratings for Apexigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apexigen and related companies with MarketBeat.com's FREE daily email newsletter.